Daesang Corp stock (KR7001680007): Food giant reports steady Q1 growth

Daesang Corp posted solid Q1 2026 results with revenue up 4.2% year-over-year, driven by strong demand in condiments and biotech segments, according to its earnings release on May 10, 2026.

Daesang Corp, a leading South Korean food and biotech company, released its first-quarter 2026 earnings on May 10, 2026, showing revenue of 1.85 trillion KRW, a 4.2% increase from the prior year. Net profit rose 6.1% to 85 billion KRW, beating analyst expectations amid robust sales in its core seasoning business. The results were published on the company's investor relations site Daesang IR as of 05/10/2026.

The stock traded at 152,000 KRW on May 14, 2026, on the Korea Exchange (KRX), up 1.2% from the previous close, according to Yahoo Finance as of 05/14/2026. This performance reflects investor confidence in Daesang's diversified portfolio, which includes popular brands like Chungjungone soy sauce.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Daesang Corp
• Sector/industry: Food processing and biotechnology
• Headquarters/country: South Korea
• Core markets: Asia, with growing US exports
• Key revenue drivers: Condiments, sweeteners, bio ingredients
• Home exchange/listing venue: Korea Exchange (KRX: 000155)
• Trading currency: KRW

Daesang Corp: core business model

Daesang Corp operates as a major player in South Korea's food industry, producing seasonings, oils, sweeteners, and biotech products. Founded in 1949, the company has expanded into functional ingredients and fermentation technology, serving both consumer and industrial markets. Its business spans B2C brands and B2B supplies to global food manufacturers.

Revenue is split across food (65%), biotech (20%), and chemicals (15%), based on the 2025 annual report published March 15, 2026 Daesang annual report as of 03/15/2026. This diversification helps buffer against commodity price swings in the food sector.

Main revenue and product drivers for Daesang Corp

The condiments division, featuring soy sauce and gochujang, generated 1.2 trillion KRW in Q1 2026, up 5% year-over-year, fueled by domestic demand and exports to the US. Biotech products like amino acids contributed 370 billion KRW, benefiting from health trends. Overseas sales rose 8%, with North America accounting for 12% of total revenue per the Q1 release.

Key brands include CJ CheilJedang collaborations and private-label supplies. Daesang's investment in sustainable sourcing supports margin stability at 12.4% EBITDA in Q1, as reported on May 10, 2026.

Industry trends and competitive position

South Korea's food sector grows at 3.5% annually through 2030, per Statista as of 04/2026, driven by premiumization and exports. Daesang holds 25% domestic market share in soy sauce, competing with Yamasa and Kikkoman internationally.

In biotech, Daesang leverages fermentation tech for MSG and nucleotides, positioning it well against global peers like Ajinomoto. US market exposure via exports ties it to American consumer trends in Asian cuisine.

Why Daesang Corp matters for US investors

Daesang's US revenue from food exports reached $250 million in 2025, per annual filings, linking it to rising demand for Korean flavors in American supermarkets. Listed as an ADR-eligible stock, it offers US investors access to Asia's food boom without direct Korea exposure risks. KRX trading provides liquidity for international portfolios.

Main revenue and product drivers for Daesang Corp

Recent capacity expansions in bio-plants boost output by 15%, supporting 2026 guidance of 7-9% revenue growth. Q1 results affirm this outlook amid stable raw material costs.

Conclusion

Daesang Corp's Q1 2026 earnings highlight resilient growth in food and biotech amid favorable market dynamics. With strong export momentum to the US and diversified revenue streams, the company maintains a solid position. Investors track upcoming Q2 results and global expansion for further insights.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.